TSX: ACB TSX: CMED
EDMONTON and SASKATOON, April 4,
2018 /CNW/ - Aurora Cannabis Inc. ("Aurora") (TSX:
ACB) (OTCQB: ACBFF) (Frankfurt:
21P; WKN: A1C4WM) and CanniMed Therapeutics Inc.
("CanniMed") (TSX: CMED) announced today that CanniMed has
entered into a Letter of Intent to become a preferred supplier of
medical cannabis to Pharmasave. A member governed cooperative of
more than 650 independently owned community pharmacies across the
country, Pharmasave is one of Canada's leading independent community
pharmacies.
Subject to changes to regulations that would allow such
distribution, CanniMed and Aurora will supply and distribute
high-quality medical cannabis, produced at the companies' GMP
compliant and GMP certified facilities, through Pharmasave
pharmacists across Canada.
Pharmasave recognized some time ago that pharmacists need to be
prepared to fulfil their role as medication experts in the area of
medical cannabis. As such, for more than a year, Pharmasave has
been educating Pharmasave pharmacists to ensure they are prepared
to support patients and physicians in medication management. This
includes how medical cannabis may affect other medications the
patient may take, any health conditions they might have, and
insights on how to identify and address mental health and addiction
concerns in patients. CanniMed has supported this commitment to
understanding medical cannabis with product information, access to
medical experts and updates on the latest research and clinical
information available. In addition to supplying Pharmasave
pharmacists with medical cannabis once permitted, CanniMed and
Aurora will continue to provide pharmacists with education related
to medical cannabis.
"Canadians trust pharmacists to help guide them to the right
information and products to treat their conditions," said
Terry Booth, Aurora CEO, "and now
Pharmasave joins two other national pharmacy chains in showing
their trust in us to provide them with medical cannabis products
and education. These supply agreements allow us strong penetration
into what is likely to be a sizable portion of the medical cannabis
market, and they highlight the strength of our organizations, the
scale of our operations and the world-class operational standards
that both Aurora and CanniMed practice. We're proud to partner with
Pharmasave and expand our ability to help Canadians in need find
the relief they are seeking."
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises
Inc., is a licensed producer of medical cannabis pursuant to Health
Canada's Access to Cannabis for Medical Purposes Regulations
("ACMPR"). The Company operates a 55,200 square foot,
state-of-the-art production facility in Mountain View County,
Alberta, known as "Aurora
Mountain", and a second 40,000 square foot high-technology
production facility known as "Aurora Vie" in Pointe-Claire, Quebec on Montreal's West Island. In January 2018, Aurora's 800,000 square foot
flagship cultivation facility, Aurora Sky, located at the
Edmonton International Airport,
was licensed. Once at full capacity, Aurora Sky is expected to
produce over 100,000 kg per annum of cannabis. Aurora is
completing a fourth facility in Lachute,
Quebec utilizing its wholly owned subsidiary Aurora Larssen
Projects Inc.
Aurora is close to completion of the acquisition of all the
outstanding shares of CanniMed Therapeutics Inc, Canada's most experienced licensed producer of
medical cannabis, adding over 20,000 kg per annum in funded
capacity, as well as Canada's
strongest medical cannabis brand.
Aurora also owns Berlin-based
Pedanios, the leading wholesale importer, exporter, and distributor
of medical cannabis in the European Union. The Company owns 51% of
Aurora Nordic, which will be constructing a 1,000,000 square foot
hybrid greenhouse in Odense,
Denmark. The Company offers further differentiation through
its acquisition of BC Northern Lights Ltd. and Urban Cultivator
Inc., industry leaders, respectively, in the production and sale of
proprietary systems for the safe, efficient and high-yield indoor
cultivation of cannabis, and in state-of-the-art indoor gardening
appliances for the cultivation of organic microgreens, vegetables
and herbs in home and professional kitchens.
Aurora holds a 19.88% ownership interest in Liquor Stores N.A.,
who intend to develop a cannabis retail network in Western Canada. In addition, the Company holds
approximately 17.23% of the issued shares in leading extraction
technology company Radient Technologies Inc., and has a strategic
investment in Hempco Food and Fiber Inc., with options to increase
ownership stake to over 50%. Aurora is also the cornerstone
investor in two other licensed producers, with a 22.9% stake in
Cann Group Limited, the first Australian company licensed to
conduct research on and cultivate medical cannabis, and a 17.62%
stake in Canadian producer The Green Organic Dutchman Ltd., with
options to increase to majority ownership.
Aurora's Common Shares trade on the TSX under the symbol
"ACB".
About CanniMed Therapeutics
CanniMed is a Canadian-based, international plant
biopharmaceutical company and a leader in the Canadian medical
cannabis industry, with 17 years of pharmaceutical cannabis
cultivation experience, state-of-the-art, GMP-compliant production
process and world class research and development platforms with a
wide range of pharmaceutical-grade cannabis products.
CanniMed, through its subsidiaries, was the first producer to be
licensed under the Marihuana for Medical Purposes Regulations, the
predecessor to the current Access to Cannabis for Medical Purposes
Regulations. It was the sole supplier to Health
Canada under the former medical marijuana system for 13 years
and has been producing safe and consistent medical cannabis for
thousands of Canadian patients, with no incident of product
diversion or recalls.
For more information, please visit our
websites: www.cannimed.ca
Forward looking statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"). Forward-looking
statements are frequently characterized by words such as "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. These statements are only predictions.
Various assumptions were used in drawing the conclusions or making
the projections contained in the forward-looking statements
throughout this news release. Forward-looking statements are based
on the opinions and estimates of management at the date the
statements are made, and are subject to a variety of risks and
uncertainties and other factors that could cause actual events or
results to differ materially from those projected in the
forward-looking statements. The Company is under no obligation, and
expressly disclaims any intention or obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as expressly
required by applicable law.
Neither TSX nor its Regulation Services Provider (as that
term is defined in the policies of Toronto Stock Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
AURORA CANNABIS
INC.
|
CanniMed Therapeutics
Inc
|
Terry
Booth
|
André
Jérôme
|
CEO
|
Interim
CEO
|
SOURCE Aurora Cannabis Inc.